Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To analyze the efficacy and safety of nusinersen in patients with spinal muscular atrophy (SMA) type I with chronic re spiratory failure. Materials and Methods: We retrospectively reviewed seven patients diagnosed with SMA type I and chronic respiratory failure who were on permanent ventilation and treated with nusinersen at Gangnam Severance Hospital between January 2018 and July 2023. Patient demographics and clinical characteristics were recorded, and treatment progress was evaluated according to Ham mersmith Infant Neurological Examination (HINE-2) and Children’s Hospital of Philadelphia Infant Test of Neuromuscular Dis orders (CHOP-INTEND) scores. Results: Patients initially developed hypotonia at a mean age of 3.7 months. Mean age at start of nusinersen was 7.3 years; the mean duration of follow-up after starting nusinersen was 46.2 months. At 6-, 18-, 38-, 58-, and 74-month follow-up, the mean changes in CHOP-INTEND scores were 1.0, 2.9, 1.8, 1.5, and 1.5, respectively, and the proportions of patients who showed disease amelioration were 28.6%, 71.4%, 75.0%, 100%, and 100%, respectively. Conclusion: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.
Abstract
Purpose: To analyze the efficacy and safety of nusinersen in patients with spinal muscular atrophy (SMA) type I with chronic re spiratory failure. Materials and Methods: We retrospectively reviewed seven patients diagnosed with SMA type I and chronic respiratory failure who were on permanent ventilation and treated with nusinersen at Gangnam Severance Hospital between January 2018 and July 2023. Patient demographics and clinical characteristics were recorded, and treatment progress was evaluated according to Ham mersmith Infant Neurological Examination (HINE-2) and Children’s Hospital of Philadelphia Infant Test of Neuromuscular Dis orders (CHOP-INTEND) scores. Results: Patients initially developed hypotonia at a mean age of 3.7 months. Mean age at start of nusinersen was 7.3 years; the mean duration of follow-up after starting nusinersen was 46.2 months. At 6-, 18-, 38-, 58-, and 74-month follow-up, the mean changes in CHOP-INTEND scores were 1.0, 2.9, 1.8, 1.5, and 1.5, respectively, and the proportions of patients who showed disease amelioration were 28.6%, 71.4%, 75.0%, 100%, and 100%, respectively. Conclusion: Nusinersen is safe and effective in patients with SMA type I, even those with chronic respiratory failure and those on permanent ventilation. No significant adverse effects of nusinersen were observed.
참고문헌 (24)
- Mercuri E, "Nusinersen in adults with spinal muscular atrophy : new challenges", Lancet Neurol, 19, pp.283~284 (2020)
- Li W, "How do SMA-linked mutations of SMN1 lead to structural", functional deficiency of the SMA protein?, 2017, pp.12, e0178519~
- Coratti G, "Motor function in type 2 and 3 SMA patients treated with nusinersen : a critical review and meta-analysis", Orphanet J Rare Dis, 16, pp.430~ (2021)
- Corey DR, "Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy", Nat Neurosci, 20, pp.497~499 (2017)
- Qing Li, "Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy", Yonsei Medical Journal, 61(4), pp.273~283 (2020), 연세대학교의과대학[DOI]
- Finkel RS, "Nusinersen versus sham control in infantile-onset spinal muscular atrophy", N Engl J Med, 377, pp.1723~1732 (2017)
- Mercuri E, "Nusinersen versus sham control in later-onset spinal muscular atrophy", N Engl J Med, 378, pp.625~635 (2018)
- De Vivo DC, "Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy : interim efficacy and safety results from the phase 2 NURTURE study", Neuromuscul Disord, 29, pp.842~856 (2019)
- Shin HJ, "Nusinersen for spinal muscular atrophy types II and III : a retrospective single-center study in South Korea", World J Pediatr, 19, pp.450~459 (2023)
- Hagenacker T, "Nusinersen in adults with 5q spinal muscular atrophy : a non-interventional, multicentre, observational cohort study", Lancet Neurol, 19, pp.317~325 (2020)
- Moshe-Lilie O, "Nusinersen in adult patients with spinal muscular atrophy : observations from a single center", Neurology, 95, pp.e413~e416 (2020)
- Ergenekon AP, "Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen", Pediatr Int, 64, pp.e15175~ (2022)
- Kolb SJ, "Natural history of infantile-onset spinal muscular atrophy", Ann Neurol, 82, pp.883~891 (2017)
- Venkataraman ST, "Pediatric critical care", pp.683~718 (2006), Mosby
- 박성훈, "Home mechanical ventilation: back to basics", Acute and Critical Care, 35(3), pp.131~141 (2020), 대한중환자의학회[DOI]
- Mahajan R, "Onasemnogene abeparvovec for spinal muscular atrophy : the costlier drug ever", Int J Appl Basic Med Res, 9, pp.127~128 (2019)
- Dangouloff T, "Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments", Orphanet J Rare Dis, 16, pp.47~ (2021)
- Aragon-Gawinska K, "Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen", Dev Med Child Neurol, 62, pp.310~314 (2020)
- Pane M, "Nusinersen in type 1 spinal muscular atrophy : twelve-month real-world data", Ann Neurol, 86, pp.443~451 (2019)
- Aragon-Gawinska K, "Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 : a cohort study", Neurology, 91, pp.e1312~e1318 (2018)
- Mercuri E, "Childhood spinal muscular atrophy : controversies and challenges", Lancet Neurol, 11, pp.443~452 (2012)
- Kayadjanian N, "SMA-EUROPE workshop report : opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe", Orphanet J Rare Dis, 8, pp.44~ (2013)
- Kim AR, "Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy : a retrospective study", Ann Indian Acad Neurol, 23, pp.796~801 (2020)
- Chan SH, "Nusinersen in spinal muscular atrophy type 1 from neonates to young adult : 1-year data from three Asia-Pacific regions", J Neurol Neurosurg Psychiatry, 92, pp.1244~1246 (2021)